Chronic hepatitis B virus;Hépatite chronique virale B

Revue Francaise des Laboratoires

Volumn 2003, Issue 358, 2003, Pages 31-37

  Buffet, Catherine ^a  

^a BICÊTRE HOSPITAL   (France)

Author keywords

Biopsy; Chronic hepatitis; Cirrhosis; HBe Ag negative; HBe positive; HBV; Liver cancer

Indexed keywords

ADEFOVIR DIPIVOXIL; ALCOHOL; ALPHA INTERFERON; AMINOTRANSFERASE; ANTIVIRUS AGENT; BIOLOGICAL MARKER; DNA POLYMERASE; HEMOGLOBIN E; HEPATITIS B ANTIBODY; HEPATITIS B VACCINE; IMMUNOMODULATING AGENT; LAMIVUDINE; NUCLEOTIDE DERIVATIVE; VIRUS DNA; VIRUS ENZYME;

ALCOHOL CONSUMPTION; AMINOTRANSFERASE BLOOD LEVEL; ANAMNESIS; ANTIVIRAL ACTIVITY; ASSOCIATION; CHRONIC HEPATITIS; CLINICAL FEATURE; CONCENTRATION (PARAMETERS); DELTA AGENT HEPATITIS; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFECT; DRUG POTENCY; DRUG TOLERABILITY; EPIDEMIOLOGICAL DATA; EVALUATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; LABORATORY TEST; LIVER BIOPSY; LIVER CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER INJURY; MUTATION; PHYSICAL EXAMINATION; REVIEW; RISK FACTOR; SEROLOGY; SERUM; SIDE EFFECT; VACCINATION; VIROLOGY; VIRUS MUTANT; VIRUS REPLICATION; VIRUS TRANSMISSION; WILD TYPE;

EID: 0842287373     PISSN: 03389898     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0338-9898(03)90044-8     Document Type: Review

References (23)

1. Buffet C., Perlemuter G., Le traitement des hépatites chroniques virales B par la lamivudine, Presse Méd. 30 (2001) 131-13 6.
2. Chu CJ., Lok A.S.F., Clinical utility in qualifying serum HBV DNA levels using PCR assays, J. Hepatol. 36 (2002) 549-551.
3. Doo E., Liang T.J., Molecular anatomy and pathophysiologic implications of drug resistance in hepatitis B virus infection, Gastroenterology 120 (2001) 1000-1008.
4. EASL international consensus conference on hepatitis B, J. Hepatol. 38 (2003) 533-540.
5. Hadziyannis S.J., Vassilopoulos D., Hepatitis B e Antigen-Negative Chronic Hepatitis B, Hepatology 34 (2001) 617-623.
6. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., Chang T.T., Kitis G., Rizzetto M., Marcellin P., Lim S.G., Goodman Z., Wulfsohn M.S., Xiong S., Fry J., Brosgart C.L., Adefovir dipivoxil for the treatment of Hepatitis B e Antigen-Negative Chronic Hepatitis B, N. Engl. J. Med. 348 (2003) 800-807.
7. Hsu Y.S., Chien R.N., Yeh C.T., Sheen I.S., Chiou H.Y., Chu C.M., Liaw Y.F., Long-term outcome after spontaneous HbeAg seroconversion in patients with chronic hepatitis B, Hepatology 35 (2002) 1522-1527.
8. Kappoor D., Guptan RC., Wakil S.M., Kazim S.N., Kaul R., Agarwal S.R., Raisuddin S., Hasnain S.E., Sarin S.K., Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis, J. Hepatol. 33 (2000) 308-312.
9. Lau G.K.K., He M.L., Fong D.Y.T., Bartholomeusz A., Au W.Y., Lie A.K.W., Locarnini S., Liang R., Preemptive use of lamivudine reduces hepatitis B exarcerbation after allogeneic hematopoietic cell transplantation, Hepatology 36 (2002) 702-709.
10. Leung N.W.Y., Lai C.L., Chang T.T., Guan R., Lee C.M., NG K.Y., Lim S.G., Wu P.C., Dent J.C., Edmundson S., Condreay L.D., Chien R.N., Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates : results after 3 years of therapy, Hepatology 33 (2001) 1527-1532.
11. Lok A.S.F., McMahon B.J., Chronic hepatitis B, Hepatology 34 (2001) 1225-1242.
12. Lok A.S., Heathcote E.J., Hoofnagle J.H., Management of hepatitis B : 2000-summary of a workshop, Gastroenterology 120 (2001) 1828-1853.
13. Marcellin P., Chang T.T., Lim S.G., long M.J., Sievert W., Shiffman M.L., Jeffers L., Goodman Z., Wulfsohn M.S., Xiong S., Fry J., Brosgart C.L., Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B, N. Engl. J. Med. 348 (2003) 808-816.
14. Papatheodoridis G.V., Hadziyannis S.J., Diagnostic and management of pre-core mutant chronic hepatitis B, Viral Hepat. 8 (2001) 311-321.
15. Papatheodoridis G.V., Dimou E., Laras A., Papadimitropoulos V., Hadziyannis S.J., Course of virologic breakthroughs under long-term lamivudine in HbeAg-negative precore mutant HBV liver disease, Hepatology 36 (2002) 219-226.
16. Perrillo R.P., Lai C.L., Liaw Y.F., Dienstag J.L., Schiff E.R., Schalm S.W., Heathcote E.J., Brown N.A., Atkins M., Woessner M., Gardner S.D., Predictors of HbeAg loss after lamivudine treatment for chronic hepatitis B, Hepatology 36 (2002) 186-194.
17. Rizzetto M., Efficacy of lamivudine in HbeAg-negative chronic hepatitis B, Med. Virol. 66 (2002) 435-451.
18. Santantonio T., Niro G.A., Sinisi E., Leandro G., Insalata M., Guastadisegni A., Facciorusso D., Gravinese E., Andriulli A., Pastore G., Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients : a controlled pilot study, J. Hepatol. 36 (2002) 799-804
19. Schiff E.R., Dienstag J.L., Karayalcin S., Grimm I.S., Perrillo R.P., Husa P., de Man R.A., Goodman Z., Condreay L.D., Crowther L.M., Woessner M.A., McPhillips P.J., Brown N.A., Lamivudine and 24 weeks of lamivudine/interferon combinaison therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders, J. Hepatol. 38 (2003) 818-826.
20. Sérologie des hépatites virales B et C, Une approche du dépistage et du diagnostic des hépatites virales B et C en Ile-de-France, Urcam Ile-de-France (2003).
21. Yang H., Westland C.E., Delaney W.E., Heathcote E.J., Ho V., Fry J., Brosgart C., Gibbs C.S., Miller M.D., Xiong S., Resistance surveillance in chronic hepatitis B. Patients treated with adefovir dipivoxil for up to 60 weeks, Hepatology 36 (2002) 464-473.
22. Yao F.Y., Terrault N.A., Freise C., Maslow L., Bass N.M., Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation : a comparative study using a matched, untreated cohort, Hepatology 34 (2001) 411-416.
23. Zoulim F., Werle B., Hépatite chronique virale B : actualités thérapeutiques, Gastroenterol. Clin. Biol. 25 (2001) B143-B151.